Hologic's Breast Cancer Index Test Influences Endocrine Therapy Decisions for Breast Cancer Patients
Hologic, Inc. and its subsidiary, Biotheranostics, Inc., have announced new data demonstrating the impact of the Breast Cancer Index (BCI) Test on extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive breast cancer. The BCI Test, recognized by the National Comprehensive Cancer Network and the American Society of Clinical Oncology, is the only genomic assay that predicts the likelihood of benefiting from extended endocrine therapy beyond five years. Recent analysis from the BCI Registry Study shows that physician recommendations for extended endocrine therapy increased by over 30% for patients identified by the BCI Test as likely to benefit, while recommendations decreased by nearly 40% for those unlikely to benefit. These findings will be presented at the 2026 ASCO Annual Meeting. 
